Press releases

CathWorks FFRangio® System employs drug-free, wire-free technology for comprehensive physiological assessment GALWAY, Ireland, April 20, 2026 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global...

Cardiovascular portfolio up 11% year-over-year; Cardiac Ablation Solutions grew 80% on strength of pulsed field ablation portfolio GALWAY, Ireland, Feb. 17, 2026 /PRNewswire/ -- Medtronic plc...

Deal demonstrates Medtronic's commitment to expanding pipeline through strategic investments and targeted acquisitions Exercising option to acquire will bolster Medtronic's interventional...

Symplicity blood pressure procedure is now covered for qualifying Medicare patients GALWAY, Ireland, Oct. 28, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare...

Long-term data shows significant and sustained blood pressure reductions in both office-based and 24-hour ambulatory blood pressure, reinforcing the durability, safety and effectiveness of the...

Enables intense focus on highest margin growth drivers where Medtronic has leading core competencies Leading, scaled, direct-to-consumer Diabetes business poised to become standalone company; only...

Star Jones, award winning television personality & women's heart health advocate, helps kick off heart health conversations this Mother's Day with the Medtronic 'Letter to My Mother' campaign GALWAY,

Delivering durable revenue growth with strong earnings power; strength in Pulsed Field Ablation, Pacing, Structural Heart, Diabetes, and Neuromodulation GALWAY, Ireland, Feb. 18, 2025 /PRNewswire/...

National coverage analysis is the first-of-its kind for a minimally invasive, interventional treatment for high blood pressure Milestone is supported by large public health need and robust,...

Delivering on commitments, executing ahead of expectations, and raising guidance Innovation driving sustained growth across many franchises: TAVR, PFA, Leadless Pacemakers, Diabetes, Spine, and...

The Symplicity ™ blood pressure procedure offers patients a new adjunct approach to lowering blood pressure GALWAY, Ireland, Nov. 1, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global...

Company commits to advancing clinical data for Symplicity™ with the SPYRAL Gemini clinical trial and expansion of the GSR-DEFINE clinical trial GALWAY, Ireland and WASHINGTON, Oct. 28, 2024...

Broad-based, durable growth across the company, including Cranial & Spinal Technologies, Diabetes, Cardiac Pacing, Surgical, and Structural Heart; gaining momentum as company enters new product...

New data from largest head-to-head randomized control TAVR trial demonstrates non-inferior clinical outcomes and superior valve performance for Evolut TAVR compared to Sapien™ at one year DUBLIN and

The Evolut™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access DUBLIN, March 27, 2024 /PRNewswire/ -- Medtronic plc (NYSE:...

Solid execution results in mid-single digit revenue growth, driven by broad-based strength across multiple businesses and geographies; Major innovative product approvals; Raises fiscal year...

The Symplicity™ blood pressure procedure offers patients a new adjunct approach to lowering blood pressure Approval is the culmination of ten years of clinical research and development of the...

Today, Medtronic announced the outcome of the U.S. Food & Drug Administration (FDA) Circulatory System Devices Panel (CSDP) meeting to review data presented in support of the Medtronic Symplicity...

Earnings delivered despite slower market procedure volume and supply recovery; Growth driven by TAVR, Pacing, U.S. Core Spine, and International Diabetes DUBLIN, Nov. 22, 2022 /PRNewswire/ --...

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the six-month results from the full cohort of the SPYRAL HTN-ON MED clinical trial. The data were presented...

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the company will host a webcast to provide an update on its Medtronic Coronary and Renal Denervation business...

Long-term analysis from landmark renal denervation trial presented as Late Breaking Clinical Science, published simultaneously in The Lancet Data add to growing body of evidence supporting the...

Revenue exceeds guidance, with known supply chain challenges impacting results; notable strength in Pacing, Cardiac Surgery, Core Spine in the U.S., and Diabetes in Europe DUBLIN, Aug. 23, 2022...

Partnership underscores Medtronic's commitment to investing in innovative technologies that support physicians and patients from diagnosis to treatment CathWorks' FFRangio® System provides...

Mid-single digit FY22 revenue growth; Q4 results affected by temporary global supply chain impacts and China lockdowns DUBLIN, May 26, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT) today...

Medtronic adds to SPYRAL HTN Global Clinical Program with late breaking clinical data for SPYRAL HTN-ON MED and GSR-DEFINE DUBLIN and PARIS, May 17, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT),...

The Onyx Frontier™ drug-eluting stent offers an innovative delivery system and builds upon the acute performance and clinical data from the Resolute Onyx™ drug-eluting stent DUBLIN, May 13, 2022 /

Medtronic adds to its robust clinical program with long-term data demonstrating the continued blood pressure lowering effect of the Symplicity renal denervation procedure Medtronic also completes...

Company advanced its pipeline, launched new products, won share, and delivered earnings growth despite COVID-19 impact on healthcare procedure volumes DUBLIN, Feb. 22, 2022 /PRNewswire/ --...

Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2022, which ended October 29, 2021. Key Highlights Revenue of $7.8 billion increased 3% reported...

New data from Medtronic Patient Preference study presented at TCT 2021; Medtronic adds to its clinical leadership for renal denervation with launch of the SPYRAL AFFIRM study DUBLIN and ORLANDO,...

Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) approval of its newest-generation, self-expanding transcatheter aortic...

Medtronic plc (NYSE:MDT) today announced financial results for its first quarter of fiscal year 2022, which ended July 30, 2021. Key Highlights Revenue of $8.0 Billion Increased 23% Reported and...

Medtronic Prevail DCB™ Designed to Treat Complex Lesions with Superior Deliverability, Rapid Absorption of Paclitaxel DUBLIN, July 26, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global...

Medtronic plc (NYSE:MDT) today announced financial results for its fourth quarter and fiscal year 2021, which ended April 30, 2021. The company reported fourth quarter worldwide revenue of $8.188...

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the complete two-year outcomes from the landmark Evolut Low Risk Trial comparing the minimally invasive Evolut™...

Medtronic Launches New GSR-DEFINE Study to Expand Real-World Data to 5,000 Patients DUBLIN, May 18, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today...

As TAVI Patient Population Grows, PRO+ TAVI System Launches with Four Valve Sizes and Lowest Delivery Profile DUBLIN, May 3, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global leader in...

Medtronic plc (NYSE:MDT) announced today that Sean Salmon, Executive Vice President and President, Diabetes Operating Unit has been named Executive Vice President and President, Cardiovascular...

Company Raises Revenue Growth Outlook Highlights Deep and Broad Pipeline and Technology Platforms DUBLIN, Oct. 14, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global leader in medical...

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval for new one-month of dual-antiplatelet therapy...

DUBLIN, June 25, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today reported new data from the Global SYMPLICITY Registry (GSR), which showed that...

DUBLIN, June 05, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received CE (Conformité Européenne) Mark for a one-month dual...

DUBLIN, May 18, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced Jeffrey J. Popma, M.D., professor of medicine at Harvard Medical School...

DUBLIN, March 30, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced positive results of the Onyx ONE Clear Study that evaluated Resolute Onyx DES in high bleeding risk (HBR)...

DUBLIN, March 29, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced first-ever clinical data from the SPYRAL HTN-OFF MED Pivotal Trial....

DUBLIN, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced it will begin enrollment in a pilot study evaluating the safety and efficacy of the Symplicity™ Spyral renal...

DUBLIN, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced that Sean Salmon, previously Senior Vice President (SVP) and President, Coronary and Structural Heart (CSH)...

DUBLIN and SAN FRANCISCO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) announced today late-breaking clinical data from the Onyx ONE Global Study, representing the first...

Results Announced from Two Renal Denervation Studies at EuroPCR Show Positive Outcomes in High-Risk Hypertensive Patients